fda semaglutide compounding enforcement november 2025 Beyond the Headlines: Warning Letters to GLP-1 Compounders fda semaglutide compounding enforcement november

Because of its well-established safety profile and long-term research, semaglutide is often a first choice for individuals new to GLP-1 therapy

Hyperthyroidism: This happens when your thyroid gland produces too much hormone

Patients should not assume that every new symptom is caused by Sermorelin, but recurring or worsening symptoms should not be ignored

Frequently reported side effects include: Nausea Vomiting Diarrhea Constipation Stomach pain Reduced appetite Indigestion These symptoms are generally linked to the way GLP-1 drugs affect digestion and appetite regulation

Use new sterile equipment for each preparation or administration and use a suitable sharps container [17]